T2 Biosystems' Q4 Loss Increases on Higher Expenses | GenomeWeb

NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market Tuesday that its fourth quarter and full-year 2014 loss increased as it ramped up R&D and invested in clinical trials for its T2Candida Panel and T2Dx instrument.

The Lexington, Mass.-based molecular diagnostics firm reported research and grant revenues for the quarter of $119,000, up from $55,000 in the fourth quarter of 2013. It didn't report any commercial revenues in the quarter or full year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.